A next-generation hyaluronic acid injectable offering a new approach to managing menopausal genital and sexual symptoms.
IBSA UK has announced the UK launch of Hyaluxelle®, a non-hormonal injectable hyaluronic acid treatment developed for adult women with atrophic symptoms affecting the vulvar vestibule. Indications include vaginal dryness, burning, itching and pain during intercourse at the vaginal opening (dyspareunia)[1].
Hyaluxelle® expands the treatment landscape for clinicians managing GSM, particularly for women who do not achieve symptom relief with first-line therapies or who are unable or unwilling to use hormonal options. The treatment aims to improve clarity and continuity across patient care pathways.
Genitourinary Syndrome of Menopause (GSM) is a chronic condition resulting from oestrogen deficiency, with effects across the genital, urinary and sexual systems[2]. Symptoms are degenerative in nature and rarely resolve without intervention[2]. Research suggests that at least half of post-menopausal women are affected[3], although many remain untreated due to misconceptions that symptoms are a normal consequence of ageing[4].
One of the most prevalent and distressing features of GSM is vulvovaginal atrophy. Progressive tissue changes linked to low oestrogen levels can lead to dryness, irritation, altered vaginal pH and painful intercourse. These symptoms often have a profound effect on emotional wellbeing, intimate relationships and quality of life[2–5].
Joanna, a 59-year-old woman living with severe GSM symptoms, describes the personal impact of delayed diagnosis. “I lived for years with pain, UTIs, cystitis and a loss of sensation, but every visit to my GP, even a female GP, was treated as a bladder issue. Nobody suggested it might be linked to the menopause or joined the dots, and none of the treatments I was given helped. Without the right information or support, I became desperate for answers.”
She added: “The symptoms affected everything, what I wore, how I exercised, how I slept, but the hardest part was the impact on intimacy with my husband. I withdrew from our relationship because I was scared sex would hurt, and the loss of closeness was devastating, and I no longer felt like myself. Women deserve clear explanations and real options when their symptoms are not getting better.”
Developed using IBSA’s patented NAHYCO® Hybrid Technology, Hyaluxelle® is a non-hormonal injectable formulation combining high- and low-molecular-weight hyaluronic acid. These hybrid cooperative complexes are designed to improve tissue integration and ease of administration.
The formulation enables injection at a lower viscosity while delivering the highest hyaluronic acid concentration currently available in the UK, helping to support tissue hydration, elasticity, firmness and regenerative processes[6].
Hyaluxelle® is administered via deep intradermal injections into the vulvar vestibule over two treatment sessions, spaced one month apart, with subsequent clinical evaluation[1]. Its viscoelastic and moisturising properties help rehydrate tissue and promote restoration of structure through collagen and elastin synthesis[5].
Clinical data demonstrate that Hyaluxelle® effectively improves a range of GSM-related vulvovaginal symptoms[5,7], including reductions in vaginal discomfort and pain during intercourse[7].
Further evidence indicates improvements across sexual function domains and favourable trends in selected quality-of-life outcomes[7]. Histological assessments show increased epithelial thickness, enhanced tissue regeneration and reduced inflammatory infiltration following treatment[5]. Across studies, Hyaluxelle® has been shown to be well tolerated, with no major complications reported[5,8].
